10x Genomics Q1 earnings call highlights

FierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS

FierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?

Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest Bouncer

Clinical OMICsContact Lenses Show Promise for Depression

BioPharma DiveBiogen pushing tau drug forward despite Alzheimer’s study failure

Endpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data

Endpoints NewsAstraZeneca follows Merck with Phase 3 win in bladder cancer

Endpoints NewsMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack

FierceBiotechCreate Medicines fashions $122M fundraise for in vivo CAR-T dreams

BioPharma DiveWith new data, Regenxbio to seek FDA approval of Duchenne gene therapy

Endpoints NewsHow Penn Medicine plans to use AI to train their doctors

FierceBiotechBiogen advances Alzheimer’s tau program despite midphase miss